Table 2.
Key Epidemiologic Characteristic, n (%) | All ND AML Patients N = 853 | All R/R AML Patients N = 289 |
---|---|---|
Progression from ND to R/R AML | 289 (33.9) | – |
Relapsed after initial treatment | 234 (27.4) | – |
Refractory to initial treatment | 55 (6.4) | – |
FLT3 mutation testing | ||
At initial AML diagnosis | 541 (63.4) | – |
At first R/R diagnosis | – | 72 (24.9) |
NGS testing method | 541 (100) | 72 (100) |
Other testing method | 0 | 0 |
FLT3MUT positivity among tested patientsa | ||
At initial AML diagnosis | 109 (20.1) | – |
FLT3-ITD mutation | 53 (48.6) | – |
FLT3-TKD mutation | 32 (29.4) | – |
Unspecified FLT3 mutation | 26 (23.9) | – |
At first R/R AML diagnosis | – | 14 (19.4) |
FLT3-ITD mutation | – | 9 (64.3) |
FLT3-TKD mutation | – | 6 (42.9) |
Unspecified FLT3 mutation | – | 1 (7.1) |
FLT3 testing at both initial AML and first R/R diagnoses | 54 (18.7) | |
Lost FLT3 mutation at first R/R | – | 3 (5.6) |
Gained FLT3 mutation at first R/R | – | 5 (9.3) |
FLT3-ITD vs FLT3-TKD mutation switch at first R/R | – | 3 (5.6) |
From FLT3-ITD to FLT3-TKD | – | 1 (33.3) |
From FLT3-TKD to FLT3-ITD | – | 2 (66.7) |
Notes: aPatients could harbor both FLT3-ITD and FLT3-TKD mutations, therefore, the percentages of each FLT3 mutation type may not add up to 100%.
Abbreviations: AML, acute myeloid leukemia; FLT3, FMS-like tyrosine kinase-3; ITD, internal tandem duplication; MUT, mutated; ND, newly diagnosed; NGS, next generation sequencing; R/R, relapsed or refractory; TKD, tyrosine kinase domain.